Virax Biolabs Group (NASDAQ:VRAX – Get Rating) and Lucira Health (NASDAQ:LHDXQ – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Profitability
This table compares Virax Biolabs Group and Lucira Health's net margins, return on equity and return on assets.
Get Virax Biolabs Group alerts:| Net Margins | Return on Equity | Return on Assets | |
| Virax Biolabs Group | N/A | N/A | N/A |
| Lucira Health | -67.54% | -13.55% | -8.47% |
Valuation & Earnings
This table compares Virax Biolabs Group and Lucira Health's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Virax Biolabs Group | $120,000.00 | 62.21 | -$1.71 million | N/A | N/A |
| Lucira Health | $93.06 million | 0.05 | -$64.83 million | ($3.58) | -0.04 |
Virax Biolabs Group has higher earnings, but lower revenue than Lucira Health.
Analyst Ratings
This is a breakdown of current recommendations for Virax Biolabs Group and Lucira Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Virax Biolabs Group | 0 | 0 | 0 | 0 | N/A |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
Institutional and Insider Ownership
0.5% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 57.0% of Lucira Health shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 30.4% of Lucira Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Virax Biolabs Group beats Lucira Health on 6 of the 8 factors compared between the two stocks.
About Virax Biolabs Group
(Get Rating)
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
About Lucira Health
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.